To date, these CAR-T cell products targeting CD19 have been approved for the treatment of diseases such as R/R leukemia and lymphoma, while the anti-BCMA CAR-T cell products are mainly used for the treatment of conditions such as R/R multiple myeloma (MM) [3–13]. Here, TNFRSF17 is linked to Miyoshi myopathy.